Mesenchymal stem cell: Present challenges and prospective cellular cardiomyoplasty approaches for myocardial regeneration

Antioxidants and Redox Signaling

Volumn 11, Issue 8, 2009, Pages 1841-1855

  Paul, Debayon ^a   Samuel, Samson Mathews ^a   Maulik, Nilanjana ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONNEXIN 43;

APOPTOSIS; CARDIOMYOPLASTY; CELL THERAPY; CELL TRANSDIFFERENTIATION; CELLULAR CARDIOMYOPLASTY; CLINICAL TRIAL; GAP JUNCTION; HEART INFARCTION; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART MUSCLE REGENERATION; HEART VENTRICLE REMODELING; HUMAN; IMMUNOMODULATION; MESENCHYMAL STEM CELL TRANSPLANTATION; MUSCLE REGENERATION; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; CELL DIFFERENTIATION; CELL TRANSPLANTATION; FEMALE; HEART; MESENCHYMAL STEM CELLS; MICE; MICE, INBRED C57BL; MYOCARDIAL ISCHEMIA; RATS; RATS, INBRED F344; REGENERATION;

EID: 67650229937     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/ars.2009.2455     Document Type: Review

References (143)

1. Abbott JD, Huang Y, Liu D, Hickey R, Krause DS, and Giordano FJ. Stromal cell-derived factor-1alpha plays a critical role in stem cell recruitment to the heart after myocardial infarction but is not sufficient to induce homing in the absence of injury. Circulation 110: 3300-3305, 2004.
2. Abdel-Latif A, Bolli R, Zuba-Surma EK, Tleyjeh IM, Hor-nung CA, and Dawn B. Granulocyte colony-stimulating factor therapy for cardiac repair after acute myocardial infarction: a systematic review and meta-analysis of randomized controlled trials. Am Heart J156: 216-226, e9,2008.
3. Adams GB, Chabner KT, Alley IR, Olson DP, Szcze-piorkowski ZM, Poznansky MC, Kos CH, Pollak MR, Brown EM, and Scadden DT. Stem cell engraftment at the endosteal niche is specified by the calcium-sensing receptor. Nature 439: 599-603, 2006.
4. Antonitsis P, Ioannidou-Papagiannaki E, Kaidoglou A, and Papakonstantinou C. In vitro cardiomyogenic differentiation of adult human bone marrow mesenchymal stem cells: the role of 5-azacytidine. Interact Cardiovasc Thorac Surg 6: 593-597, 2007.
5. Arminan A, Gandia C, Bartual C, Garcia-Verdugo JM, Lledo E, Mirabet V, Llop M, Barea J, Montero JA, and Se-pulveda P. Cardiac differentiation is driven by NKX2.5 and GATA4 nuclear translocation in tissue specific mesenchymal stem cells. Stem Cells Dev 2008. Nov 4 [Epub ahead of print]
6. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, and Isner JM. Isolation of putative progenitor endothelial cells for an-giogenesis. Science 275: 964-967, 1997.
7. Balana B, Nicoletti C, Zahanich I, Graf EM, Christ T, Box-berger S, and Ravens U. 5-Azacytidine induces changes in electrophysiological properties of human mesenchymal stem cells. Cell Res 16: 949-960, 2006.
8. Barile L, Messina E, Giacomello A, and Marban E. Endogenous cardiac stem cells. Prog Cardiovasc Dis 50: 31-48, 2007.
9. Bayes-Genis A, Roura S, Soler-Botija C, Farre J, Hove-Madsen L, Llach A, and Cinca J. Identification of car-diomyogenic lineage markers in untreated human bone marrow-derived mesenchymal stem cells. Transplant Proc 37: 4077-4079, 2005.
10. Bearzi C, Rota M, Hosoda T, Tillmanns J, Nascimbene A, De Angelis A, Yasuzawa-Amano S, Trofimova I, Siggins RW, Lecapitaine N, Cascapera S, Beltrami AP, D'Alessan-dro DA, Zias E, Quaini F, Urbanek K, Michler RE, Bolli R, Kajstura J, Leri A, and Anversa P. Human cardiac stem cells. Proc Natl Acad Sci U S A 104: 14068-14073, 2007.
11. Beeres SL, Atsma DE, van der Laarse A, Pijnappels DA, van Tuyn J, Fibbe WE, de Vries AA, Ypey DL, van der Wall EE, and Schalij MJ. Human adult bone marrow mesenchy-mal stem cells repair experimental conduction block in rat cardiomyocyte cultures. J Am Coll Cardiol 46: 1943-1952, 2005.
12. Beltrami AP, Barlucchi L, Torella D, Baker M, Limana F, Chimenti S, Kasahara H, Rota M, Musso E, Urbanek K, Leri A, Kajstura J, Nadal-Ginard B, and Anversa P. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell 114: 763-776, 2003.
13. Benvenuti S, Saccardi R, Luciani P, Urbani S, Deledda C, Cellai I, Francini F, Squecco R, Rosati F, Danza G, Gelmini S, Greeve I, Rossi M, Maggi R, Serio M, and Peri A. Neu-ronal differentiation of human mesenchymal stem cells: changes in the expression of the Alzheimer's disease-related gene seladin-1. Exp Cell Res 312: 2592-2604, 2006.
14. Bonaros N, Rauf R, Schachner T, Laufer G, and Kocher A. Enhanced cell therapy for ischemic heart disease. Transplantation 86: 1151-1160, 2008.
15. Bongso A, Fong CY, and Gauthaman K. Taking stem cells to the clinic: major challenges. J Cell Biochem 105: 1352-1360, 2008.
16. Cao F, Wagner RA, Wilson KD, Xie X, Fu JD, Drukker M, Lee A, Li RA, Gambhir SS, Weissman IL, Robbins RC, and Wu JC. Transcriptional and functional profiling of human embryonic stem cell-derived cardiomyocytes. PLoS ONE 3:e3474, 2008.
17. Caplan A. Why are MSCs therapeutic? New data: new insight. J Pathol 217: 318-324, 2009.
18. Caplan AI. All MSCs are pericytes? Cell Stem Cell 3: 229-230, 2008.
19. Chang SA, Lee EJ, Kang HJ, Zhang SY, Kim JH, Li L, Youn SW, Lee CS, Kim KH, Won JY, Sohn JW, Park KW, Cho HJ, Yang SE, Oh WI, Yang YS, Ho WK, Park YB, and Kim HS. Impact of myocardial infarct proteins and oscillating pressure on the differentiation of mesenchymal stem cells: effect of acute myocardial infarction on stem cell differentiation. Stem Cells 26: 1901-1912, 2008.
20. Charwat S, Gyongyosi M, Lang I, Graf S, Beran G, He-metsberger R, Nyolczas N, Sochor H, and Glogar D. Role of adult bone marrow stem cells in the repair of ischemic myocardium: current state of the art. Exp Hematol 36: 672-680, 2008.
21. Chen CH, Wei HJ, Lin WW, Chiu I, Hwang SM, Wang CC, Lee WY, Chang Y, and Sung HW. Porous tissue grafts sandwiched with multilayered mesenchymal stromal cell sheets induce tissue regeneration for cardiac repair. Cardi-ovasc Res 80: 88-95, 2008.
22. Chen S, Liu Z, Tian N, Zhang J, Yei F, Duan B, Zhu Z, Lin S, and Kwan TW. Intracoronary transplantation of autolo-gous bone marrow mesenchymal stem cells for ischemic cardiomyopathy due to isolated chronic occluded left anterior descending artery. J Invas Cardiol 18: 552-556, 2006.
23. Chen SL, Fang WW, Ye F, Liu YH, Qian J, Shan SJ, Zhang JJ, Chunhua RZ, Liao LM, Lin S, and Sun JP. Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. Am J Cardiol 94: 92-95, 2004.
24. Cheng Z, Ou L, Zhou X, Li F, Jia X, Zhang Y, Liu X, Li Y, Ward CA, Melo LG, and Kong D. Targeted migration of mesenchymal stem cells modified with CXCR4 gene to infarcted myocardium improves cardiac performance. Mol Ther 16: 571-579, 2008.
25. da Silva Meirelles L, Caplan AI, and Nardi NB. In search of the in vivo identity of mesenchymal stem cells. Stem Cells 26: 2287-2299, 2008.
26. da Silva Meirelles L, Chagastelles PC, and Nardi NB. Me-senchymal stem cells reside in virtually all post-natal organs and tissues. J Cell Sci 119: 2204-2213, 2006.
27. Dai W and Kloner RA. Myocardial regeneration by embryonic stem cell transplantation: present and future trends. Expert Rev Cardiovasc Ther 4: 375-383, 2006.
28. Dawn B and Bolli R. Bone marrow for cardiac repair: the importance of characterizing the phenotype and function of injected cells. Eur Heart J 28: 651-652, 2007.
29. Dawn B and Bolli R. Adult bone marrow-derived cells: regenerative potential, plasticity, and tissue commitment. Basic Res Cardiol 100: 494-503, 2005.
30. Dawn B, Stein AB, Urbanek K, Rota M, Whang B, Rastaldo R, Torella D, Tang XL, Rezazadeh A, Kajstura J, Leri A, Hunt G, Varma J, Prabhu SD, Anversa P, and Bolli R. Cardiac stem cells delivered intravascularly traverse the vessel barrier, regenerate infarcted myocardium, and improve cardiac function. Proc Natl Acad Sci U S A 102: 3766-3771, 2005.
31. Dazzi F and Marelli-Berg FM. Mesenchymal stem cells for graft-versus-host disease: close encounters with T cells. Eur J Immunol 38: 1479-1482, 2008.
32. De Becker A, Van Hummelen P, Bakkus M, Vande Broek I, De Wever J, De Waele M, and Van Riet I. Migration of culture-expanded human mesenchymal stem cells through bone marrow endothelium is regulated by matrix me-talloproteinase-2 and tissue inhibitor of metalloproteinase-3. Haematologica 92: 440-449, 2007.
33. de Muinck ED, Thompson C, and Simons M. Progress and prospects: cell based regenerative therapy for cardiovascular disease. Gene Ther 13: 659-671, 2006.
34. Dellatore SM, Garcia AS, and Miller WM. Mimicking stem cell niches to increase stem cell expansion. Curr Opin Bio-technol 19: 534-540, 2008.
35. Delorme B, Chateauvieux S, and Charbord P. The concept of mesenchymal stem cells. Regen Med 1: 497-509, 2006.
36. Dimmeler S and Zeiher AM. Cell therapy of acute myocar-dial infarction: open questions. Cardiology 113: 155-160, 2008.
37. Eaves C. Hematopoietic stem cells get closer to the bone. Nat Med 10: 1042-1044, 2004.
38. Eguchi M, Masuda H, and Asahara T. Endothelial progenitor cells for postnatal vasculogenesis. Clin Exp Nephrol11: 18-25, 2007.
39. Evans MJ and Kaufman MH. Establishment in culture of pluripotential cells from mouse embryos. Nature 292: 154-156, 1981.
40. Friedenstein AJ, Chailakhyan RK, Latsinik NV, Panasyuk AF, and Keiliss-Borok IV. Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues: cloning in vitro and retransplantation in vivo. Transplantation 17: 331-340, 1974.
41. Garry DJ and Olson EN. A common progenitor at the heart of development. Cell 127: 1101-1104, 2006.
42. Glennie S, Soeiro I, Dyson PJ, Lam EW, and Dazzi F. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 105: 2821-2827, 2005.
43. Gnecchi M, He H, Liang OD, Melo LG, Morello F, Mu H, Noiseux N, Zhang L, Pratt RE, Ingwall JS, and Dzau VJ. Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med 11: 367-368, 2005.
44. Gurtner GC and Chang E. "Priming" endothelial progenitor cells: a new strategy to improve cell based therapeutics. Arterioscler Thromb Vasc Biol 28: 1034-1035, 2008.
45. Hahn JY, Cho HJ, Kang HJ, Kim TS, Kim MH, Chung JH, Bae JW, Oh BH, Park YB, and Kim HS. Pre-treatment of mesenchymal stem cells with a combination of growth factors enhances gap junction formation, cytoprotective effect on cardiomyocytes, and therapeutic efficacy for myo-cardial infarction. J Am Coll Cardiol 51: 933-943, 2008.
46. Haider H, Jiang S, Idris NM, and Ashraf M. IGF-1-overexpressing mesenchymal stem cells accelerate bone marrow stem cell mobilization via paracrine activation of SDF-1alpha/CXCR4 signaling to promote myocardial repair. Circ Res 103: 1300-1308, 2008.
47. Haider H, Ye L, Jiang S, Ge R, Law PK, Chua T, Wong P, and Sim EK. Angiomyogenesis for cardiac repair using human myoblasts as carriers of human vascular endothelial growth factor. J Mol Med 82: 539-549, 2004.
48. Horwitz EM, Le Blanc K, Dominici M, Mueller I, Slaper-Cortenbach I, Marini FC, Deans RJ, Krause DS, and Keating A. Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. Cytotherapy 7: 393-395, 2005.
49. Hu X, Yu SP, Fraser JL, Lu Z, Ogle ME, Wang JA, and Wei L. Transplantation of hypoxia-preconditioned mesenchy-mal stem cells improves infarcted heart function via enhanced survival of implanted cells and angiogenesis. J Thorac Cardiovasc Surg 135: 799-808, 2008.
50. Ip JE, Wu Y, Huang J, Zhang L, Pratt RE, and Dzau VJ. Mesenchymal stem cells use integrin beta1 not CXC che-mokine receptor 4 for myocardial migration and engraft-ment. Mol Biol Cell 18: 2873-2882, 2007.
51. Ishikawa F, Shimazu H, Shultz LD, Fukata M, Nakamura R, Lyons B, Shimoda K, Shimoda S, Kanemaru T, Naka-mura K, Ito H, Kaji Y, Perry AC, and Harada M. Purified human hematopoietic stem cells contribute to the generation of cardiomyocytes through cell fusion. FASEB J 20:950-952, 2006.
52. Iwami Y, Masuda H, and Asahara T. Endothelial progenitor cells: past, state of the art, and future. J Cell Mol Med 8:488-497, 2004.
53. Jazayeri M, Allameh A, Soleimani M, Jazayeri SH, Piryaei A, and Kazemnejad S. Molecular and ultrastructural characterization of endothelial cells differentiated from human bone marrow mesenchymal stem cells. Cell Biol Int 32:1183-1192, 2008.
54. Kadivar M, Khatami S, Mortazavi Y, Shokrgozar MA, Taghikhani M, and Soleimani M. In vitro cardiomyogenic potential of human umbilical vein-derived mesenchymal stem cells. Biochem Biophys Res Commun 340: 639-647, 2006.
55. Kaplan RN, Psaila B, and Lyden D. Niche-to-niche migration of bone-marrow-derived cells. Trends Mol Med 13: 72-81, 2007.
56. Kawakami K and Parker DC. Differences between T helper cell type I (Th1) and Th2 cell lines in signalling pathways for induction of contact-dependent T cell help. Eur J Immunol 22: 85-93, 1992.
57. Kiel MJ and Morrison SJ. Maintaining hematopoietic stem cells in the vascular niche. Immunity 25: 862-864, 2006.
58. Kumar D, Kamp TJ, and LeWinter MM. Embryonic stem cells: differentiation into cardiomyocytes and potential for heart repair and regeneration. Coron Artery Dis 16: 111-116, 2005.
59. Kurdi M and Booz GW. G-CSF-based stem cell therapy for the heart-unresolved issues part A: paracrine actions, mobilization, and delivery. Congest Heart Fail 13: 221-227, 2007.
60. Le Blanc K and Ringden O. Immunomodulation by mes-enchymal stem cells and clinical experience. J Intern Med 262: 509-525, 2007.
61. Leri A, Kajstura J, Anversa P, and Frishman WH. Myo-cardial regeneration and stem cell repair. Curr Probl Cardiol 33: 91-153, 2008.
62. Levesque JP and Winkler IG. Mobilization of hematopoietic stem cells: state of the art. Curr Opin Organ Transplant 13:53-58, 2008.
63. Li Q, Xu X, Wang Z, Liu W, and Li Z. [Investigation of canine mesenchymal stem cells differentiation to vascular endothelial cell in vitro]. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi 24: 1348-1351, 2007.
64. Li W, Ma N, Ong LL, Nesselmann C, Klopsch C, Ladilov Y, Furlani D, Piechaczek C, Moebius JM, Lutzow K, Lendlein A, Stamm C, Li RK, and Steinhoff G. Bcl-2 engineered MSCs inhibited apoptosis and improved heart function. Stem Cell 25: 2118-2127, 2007.
65. Li Z, Wu JC, Sheikh AY, Kraft D, Cao F, Xie X, Patel M, Gambhir SS, Robbins RC, and Cooke JP. Differentiation,survival, and function of embryonic stem cell derived en-dothelial cells for ischemic heart disease. Circulation 116:I46-154, 2007.
66. Losordo DW and Dimmeler S. Therapeutic angiogenesis and vasculogenesis for ischemic disease, part II: cell-based therapies. Circulation 109: 2692-2697, 2004.
67. Lowry WE, Richter L, Yachechko R, Pyle AD, Tchieu J, Sridharan R, Clark AT, and Plath K. Generation of human induced pluripotent stem cells from dermal fibroblasts. Proc Natl Acad Sci U S A 105: 2883-2888, 2008.
68. Majhail NS, Parks K, Defor TE, and Weisdorf DJ. Diffuse alveolar hemorrhage and infection-associated alveolar hemorrhage following hematopoietic stem cell transplantation: related and high-risk clinical syndromes. Biol Blood Marrow Transplant 12: 1038-1046, 2006.
69. Mangi AA, Noiseux N, Kong D, He H, Rezvani M, Ingwall JS, and Dzau VJ. Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of in-farcted hearts. Nat Med 9: 1195-1201, 2003.
70. Martin GR. Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by te-ratocarcinoma stem cells. Proc Natl Acad Sci U S A 78: 7634-7638, 1981.
71. Mauritz C, Schwanke K, Reppel M, Neef S, Katsirntaki K, Maier LS, Nguemo F, Menke S, Haustein M, Hescheler J, Hasenfuss G, and Martin U. Generation of functional mu-rine cardiac myocytes from induced pluripotent stem cells. Circulation 118: 507-517, 2008.
72. Menasche P. Skeletal myoblasts as a therapeutic agent. Prog Cardiovasc Dis 50: 7-17, 2007.
73. Miyahara Y, Nagaya N, Kataoka M, Yanagawa B, Tanaka K, Hao H, Ishino K, Ishida H, Shimizu T, Kangawa K, Sano S, Okano T, Kitamura S, and Mori H. Monolayered mes-enchymal stem cells repair scarred myocardium after myocardial infarction. Nat Med 12: 459-465, 2006.
74. Mohyeddin-Bonab M, Mohamad-Hassani MR, Alimo-ghaddam K, Sanatkar M, Gasemi M, Mirkhani H, Radmehr H, Salehi M, Eslami M, Farhig-Parsa A, Emami-Razavi H, Alemohammad MG, Solimani AA, Ghavamzadeh A, and Nikbin B. Autologous in vitro expanded mesenchymal stem cell therapy for human old myocardial infarction. Arch Iran Med 10: 467-473, 2007.
75. Murry CE, Wiseman RW, Schwartz SM, and Hauschka SD. Skeletal myoblast transplantation for repair of myocardial necrosis. J Clin Invest 98: 2512-2523, 1996.
76. Nagaya N, Kangawa K, Itoh T, Iwase T, Murakami S, Miyahara Y, Fujii T, Uematsu M, Ohgushi H, Yamagishi M, Tokudome T, Mori H, Miyatake K, and Kitamura S. Transplantation of mesenchymal stem cells improves cardiac function in a rat model of dilated cardiomyopathy. Circulation 112: 1128-1135, 2005.
77. Nakanishi C, Yamagishi M, Yamahara K, Hagino I, Mori H, Sawa Y, Yagihara T, Kitamura S, and Nagaya N. Activation of cardiac progenitor cells through paracrine effects of mesenchymal stem cells. Biochem Biophys Res Commun 374: 11-16, 2008.
78. Narazaki G, Uosaki H, Teranishi M, Okita K, Kim B, Matsuoka S, Yamanaka S, and Yamashita JK. Directed and systematic differentiation of cardiovascular cells from mouse induced pluripotent stem cells. Circulation 118: 498-506, 2008.
79. Niagara MI, Haider H, Jiang S, and Ashraf M. Pharmacologically preconditioned skeletal myoblasts are resistant to oxidative stress and promote angiomyogenesis via release of paracrine factors in the infarcted heart. Circ Res 100: 545-555, 2007.
80. Norol F, Bonnet N, Peinnequin A, Chretien F, Legrand R, Isnard R, Herodin F, Baillou C, Delache B, Negre D, Klatzmann D, Vernant JP, and Lemoine FM. GFP-transduced CD34+ and Lin-CD34-hematopoietic stem cells did not adopt a cardiac phenotype in a nonhuman primate model of myocardial infarct. Exp Hematol 35: 653-661, 2007.
81. Novotny NM, Ray R, Markel TA, Crisostomo PR, Wang M, Wang Y, and Meldrum DR. Stem cell therapy in myocar-dial repair and remodeling. J Am Coll Surg 207: 423-434, 2008.
82. Ohnishi S and Nagaya N. Prepare cells to repair the heart: mesenchymal stem cells for the treatment of heart failure. Am J Nephrol 27: 301-307, 2007.
83. Orlic D, Kajstura J, Chimenti S, Jakoniuk I, Anderson SM, Li B, Pickel J, McKay R, Nadal-Ginard B, Bodine DM, Leri A, and Anversa P. Bone marrow cells regenerate infarcted myocardium. Nature 410: 701-705, 2001.
84. Oswald J, Boxberger S, Jorgensen B, Feldmann S, Ehninger G, Bornhauser M, and Werner C. Mesenchymal stem cells can be differentiated into endothelial cells in vitro. Stem Cells 22: 377-384, 2004.
85. Pasha Z, Wang Y, Sheikh R, Zhang D, Zhao T, and Ashraf M. Preconditioning enhances cell survival and differentiation of stem cells during transplantation in infarcted myocardium. Cardiovasc Res 77: 134-142, 2008.
86. Pedemonte E, Benvenuto F, Casazza S, Mancardi G, Oksenberg JR, Uccelli A, and Baranzini SE. The molecular signature of therapeutic mesenchymal stem cells exposes the architecture of the hematopoietic stem cell niche synapse. BMC Genomics 8: 65, 2007.
87. Pedrotty DM, Klinger RY, Badie N, Hinds S, Kardashian A, and Bursac N. Structural coupling of cardiomyocytes and noncardiomyocytes: quantitative comparisons using a novel micropatterned cell pair assay. Am J Physiol Heart Circ Physiol 295: H390-H400, 2008.
88. Pitchford SC, Furze RC, Jones CP, Wengner AM, and Rankin SM. Differential mobilization of subsets of progenitor cells from the bone marrow. Cell Stem Cell 4: 62-72, 2009.
89. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, and Marshak DR. Multilineage potential of adult human mes-enchymal stem cells. Science 284: 143-147, 1999.
90. Pons J, Huang Y, Arakawa-Hoyt J, Washko D, Takagawa J, Ye J, Grossman W, and Su H. VEGF improves survival of mesenchymal stem cells in infarcted hearts. Biochem Biophys Res Commun 376: 419-422, 2008.
91. Potapova I, Plotnikov A, Lu Z, Danilo P Jr, Valiunas V, Qu J, Doronin S, Zuckerman J, Shlapakova IN, Gao J, Pan Z, Herron AJ, Robinson RB, Brink PR, Rosen MR, and Cohen IS. Human mesenchymal stem cells as a gene delivery system to create cardiac pacemakers. Circ Res 94: 952-959, 2004.
92. Psaltis PJ, Zannettino AC, Worthley SG, and Gronthos S. Concise review: mesenchymal stromal cells: potential for cardiovascular repair. Stem Cells 26: 2201-2210, 2008.
93. Rafii S and Lyden D. Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat Med 9: 702-712, 2003.
94. Rangappa S, Fen C, Lee EH, Bongso A, and Sim EK. Transformation of adult mesenchymal stem cells isolated from the fatty tissue into cardiomyocytes. Ann Thorac Surg 75: 775-779, 2003.
95. Raya A, Rodriguez-Piza I, Aran B, Consiglio A, Barri PN, Veiga A, and Izpisua Belmonte JC. Generation of cardio-myocytes from new human embryonic stem cell lines derived from poor-quality blastocysts. Cold Spring Harb Symp Quant Biol 24: 2669-2676, 2008.
96. Reinecke H, MacDonald GH, Hauschka SD, and Murry CE. Electromechanical coupling between skeletal and cardiac muscle: implications for infarct repair. J Cell Biol 149: 731-740, 2000.
97. Reinecke H, Minami E, Zhu WZ, and Laflamme MA. Cardiogenic differentiation and transdifferentiation of progenitor cells. Circ Res 103: 1058-1071, 2008.
98. Rosova I, Dao M, Capoccia B, Link D, and Nolta JA. Hy-poxic preconditioning results in increased motility and improved therapeutic potential of human mesenchymal stem cells. Stem Cells 26: 2173-2182, 2008.
99. Rota M, Padin-Iruegas ME, Misao Y, De Angelis A, Maes-troni S, Ferreira-Martins J, Fiumana E, Rastaldo R, Arcarese ML, Mitchell TS, Boni A, Bolli R, Urbanek K, Hosoda T, Anversa P, Leri A, and Kajstura J. Local activation or implantation of cardiac progenitor cells rescues scarred in-farcted myocardium improving cardiac function. Circ Res 103: 107-116, 2008.
100. Schenk S, Mal N, Finan A, Zhang M, Kiedrowski M, Popovic Z, McCarthy PM, and Penn MS. Monocyte che-motactic protein-3 is a myocardial mesenchymal stem cell homing factor. Stem Cell 25: 245-251, 2007.
101. Segers VF and Lee RT. Stem-cell therapy for cardiac disease. Nature 451: 937-942, 2008.
102. Shake JG, Gruber PJ, Baumgartner WA, Senechal G, Meyers J, Redmond JM, Pittenger MF, and Martin BJ. Mesenchymal stem cell implantation in a swine myocardial infarct model: engraftment and functional effects. Ann Thorac Surg 73: 1919-1925; discussion 1926, 2002.
103. Shim WS, Jiang S, Wong P, Tan J, Chua YL, Tan YS, Sin YK, Lim CH, Chua T, Teh M, Liu TC, and Sim E. Ex vivo differentiation of human adult bone marrow stem cells into cardiomyocyte-like cells. Biochem Biophys Res Commun 324:481-488, 2004.
104. Simpson D, Liu H, Fan TH, Nerem R, and Dudley SC Jr. A tissue engineering approach to progenitor cell delivery results in significant cell engraftment and improved myo-cardial remodeling. Stem Cells 25: 2350-2357, 2007.
105. Singh P and Williams DJ. Cell therapies: realizing the potential of this new dimension to medical therapeutics. J Tissue Eng Regen Med 2: 307-319, 2008.
106. Smith RR, Barile L, Cho HC, Leppo MK, Hare JM, Messina E, Giacomello A, Abraham MR, and Marban E. Regenerative potential of cardiosphere-derived cells expanded from percutaneous endomyocardial biopsy specimens. Circulation 115: 896-908, 2007.
107. Soubani AO. Critical care considerations of hematopoi-etic stem cell transplantation. Crit Care Med 34: S251-S267, 2006.
108. Spaggiari GM, Capobianco A, Abdelrazik H, Becchetti F, Mingari MC, and Moretta L. Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cy-tokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood 111: 1327-1333, 2008.
109. Stewart DJ, Hilton JD, Arnold JM, Gregoire J, Rivard A, Archer SL, Charbonneau F, Cohen E, Curtis M, Buller CE, Mendelsohn FO, Dib N, Page P, Ducas J, Plante S, Sullivan J, Macko J, Rasmussen C, Kessler PD, and Rasmussen HS. Angiogenic gene therapy in patients with nonrevascula-rizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF(121) (AdVEGF121) versus maximum medical treatment. Gene Ther 13: 1503-1511, 2006.
110. Stolzing A, Sethe S, and Scutt AM. Stressed stem cells: temperature response in aged mesenchymal stem cells. Stem Cells Dev 15: 478-487, 2006.
111. Suzuki K, Murtuza B, Smolenski RT, Sammut IA, Suzuki N, Kaneda Y, and Yacoub MH. Cell transplantation for the treatment of acute myocardial infarction using vascular endothelial growth factor-expressing skeletal myoblasts. Circulation 104: I207-1212, 2001.
112. Suzuki K, Murtuza B, Suzuki N, Smolenski RT, and Yacoub MH. Intracoronary infusion of skeletal myoblasts improves cardiac function in doxorubicin-induced heart failure. Circulation 104: I213-I217, 2001.
113. Swijnenburg RJ, Tanaka M, Vogel H, Baker J, Kofidis T, Gunawan F, Lebl DR, Caffarelli AD, de Bruin JL, Fedoseyeva EV, and Robbins RC. Embryonic stem cell immunogenicity increases upon differentiation after transplantation into ischemic myocardium. Circulation 112: I166-I172, 2005.
114. Takahashi K and Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126: 663-676, 2006.
115. Takahashi T, Kalka C, Masuda H, Chen D, Silver M, Kearney M, Magner M, Isner JM, and Asahara T. Ischemia-and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med 5: 434-438, 1999.
116. Tang J, Xie Q, Pan G, Wang J, and Wang M. Mesenchymal stem cells participate in angiogenesis and improve heart function in rat model of myocardial ischemia with re-perfusion. Eur J Cardiothorac Surg 30: 353-361, 2006.
117. Tang YL, Zhao Q, Qin X, Shen L, Cheng L, Ge J, and Phillips MI. Paracrine action enhances the effects of autol-ogous mesenchymal stem cell transplantation on vascular regeneration in rat model of myocardial infarction. Ann Thorac Surg 80: 229-236; discussion 236-237, 2005.
118. Taylor DA, Atkins BZ, Hungspreugs P, Jones TR, Reedy MC, Hutcheson KA, Glower DD, and Kraus WE. Regenerating functional myocardium: improved performance after skeletal myoblast transplantation. Nat Med 4: 929-933, 1998.
119. Taylor DA, Silvestry SC, Bishop SP, Annex BH, Lilly RE, Glower DD, and Kraus WE. Delivery of primary autolo-gous skeletal myoblasts into rabbit heart by coronary infusion: a potential approach to myocardial repair. Proc Assoc Am Physicians 109: 245-253, 1997.
120. Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, and Jones JM. Embryonic stem cell lines derived from human blastocysts. Science 282:1145-1147, 1998.
121. Timmermans F, Plum J, Yoder MC, Ingram DA, Vande-kerckhove B, and Case J. Endothelial progenitor cells: identity defined? J Cell Mol Med 13: 87-102, 2008.
122. Toma C, Pittenger MF, Cahill KS, Byrne BJ, and Kessler PD. Human mesenchymal stem cells differentiate to a cardio-myocyte phenotype in the adult murine heart. Circulation 105: 93-98, 2002.
123. Tulloch NL, Pabon L, and Murry CE. Get with the (re)program: cardiovascular potential of skin-derived induced pluripotent stem cells. Circulation 118: 472-475, 2008.
124. Umemura T and Higashi Y. Endothelial progenitor cells: therapeutic target for cardiovascular diseases. J Pharmacol Sci 108: 1-6, 2008.
125. Unzek S, Zhang M, Mal N, Mills WR, Laurita KR, and Penn MS. SDF-1 recruits cardiac stem cell-like cells that depolarize in vivo. Cell Transplant 16: 879-886, 2007.
126. Valiunas V, Doronin S, Valiuniene L, Potapova I, Zucker-man J, Walcott B, Robinson RB, Rosen MR, Brink PR, and Cohen IS. Human mesenchymal stem cells make cardiac connexins and form functional gap junctions. J Physiol 555:617-626, 2004.
127. Valtieri M and Sorrentino A. The mesenchymal stromal cell contribution to homeostasis. J Cell Physiol 217: 296-300,2008.
128. Vogel G. Breakthrough of the year: reprogramming cells. Science 322: 1766-1767, 2008.
129. Wang JA, Chen TL, Jiang J, Shi H, Gui C, Luo RH, Xie XJ, Xiang MX, and Zhang X. Hypoxic preconditioning attenuates hypoxia/reoxygenation-induced apoptosis in mes-enchymal stem cells. Acta Pharmacol Sin 29: 74-82, 2008.
130. Wang JA, He A, Hu X, Jiang Y, Sun Y, Jiang J, Gui C, Wang Y, and Chen H. Anoxic preconditioning: a way to enhance the cardioprotection of mesenchymal stem cells. Int J Car-diol 133: 410-412, 2008.
131. Wang JA, Xie XJ, He H, Sun Y, Jiang J, Luo RH, Fan YQ, and Dong L. [A prospective, randomized, controlled trial of autologous mesenchymal stem cells transplantation for dilated cardiomyopathy]. Zhonghua Xin Xue Guan Bing Za Zhi 34: 107-110, 2006.
132. Wang T, Xu Z, Jiang W, and Ma A. Cell-to-cell contact induces mesenchymal stem cell to differentiate into cardi-omyocyte and smooth muscle cell. Int J Cardiol 109: 74-81, 2006.
133. Wang X, McCullough KD, Franke TF, and Holbrook NJ. Epidermal growth factor receptor-dependent Akt activation by oxidative stress enhances cell survival. J Biol Chem 275: 14624-14631, 2000.
134. Wei HJ, Chen CH, Lee WY, Chiu I, Hwang SM, Lin WW, Huang CC, Yeh YC, Chang Y, and Sung HW. Bioengi-neered cardiac patch constructed from multilayered mes-enchymal stem cells for myocardial repair. Biomaterials 29: 3547-3556, 2008.
135. Wojakowski W, Kucia M, Kazmierski M, Ratajczak MZ, and Tendera M. Circulating progenitor cells in stable coronary heart disease and acute coronary syndromes: relevant reparatory mechanism? Heart 94: 27-33, 2008.
136. Xie XJ, Wang JA, Cao J, and Zhang X. Differentiation of bone marrow mesenchymal stem cells induced by myo-cardial medium under hypoxic conditions. Acta Pharmacol Sin 27: 1153-1158, 2006.
137. Xu W, Zhang X, Qian H, Zhu W, Sun X, Hu J, Zhou H, and Chen Y. Mesenchymal stem cells from adult human bone marrow differentiate into a cardiomyocyte phenotype in vitro. Exp Biol Med (Maywood) 229: 623-631, 2004.
138. Xu YX, Chen L, Wang R, Hou WK, Lin P, Sun L, Sun Y, and Dong QY. Mesenchymal stem cell therapy for diabetes through paracrine mechanisms. Med Hypotheses 71: 390-393, 2008.
139. Zeng J, Wang Y, Wei Y, Xie A, Lou Y, and Zhang M. Co-culture with cardiomyocytes induces mesenchymal stem cells to differentiate into cardiomyocyte-like cells and express heart development-associated genes. Cell Res 18: 562, 2008.
140. Zhang D, Fan GC, Zhou X, Zhao T, Pasha Z, Xu M, Zhu Y, Ashraf M, and Wang Y. Over-expression of CXCR4 on mesenchymal stem cells augments myoangiogenesis in the infarcted myocardium. J Mol Cell Cardiol 44: 281-292, 2008.
141. Zhang M, Mal N, Kiedrowski M, Chacko M, Askari AT, Popovic ZB, Koc ON, and Penn MS. SDF-1 expression by mesenchymal stem cells results in trophic support of cardiac myocytes after myocardial infarction. FASEB J 21:3197-3207, 2007.
142. Zhao P, Ise H, Hongo M, Ota M, Konishi I, and Nikaido T.Human amniotic mesenchymal cells have some characteristics of cardiomyocytes. Transplantation 79: 528-535, 2005.
143. Zhu WZ, Hauch KD, Xu C, and Laflamme MA. Human embryonic stem cells and cardiac repair. Transplant Rev (Orlando) 23: 53-68, 2008.